Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Risk of composite adverse eventsb · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs

Sugammadex (any dose) probably leads to lower risk of composite adverse eventsb compared with neostigmine (any dose) (moderate certainty).

1 finding from 1 review

Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults 2017 · Cochrane Headline outcomes only
RR 0.6 [0.49, 0.74]
28 studies · 2298 participants
Moderate